OUR STORY
Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about us:
Ascelia Pharma Company Introduction – January 2024
TOP STORIES
Ascelia Pharma Secures Financing of up to SEK 35 Million
2024-02-04 20:54:00
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRI …
TOP STORIES
Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024
2023.08.08
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the image reading phase has started as […]
TOP STORIES
NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB
2023-10-19 18:50:00
The shareholders in Ascelia Pharma AB, Reg. No. 556571-8797, are hereby invited to the extraordinary general meeting (Sw. extra bolagsstämma) to be held at the premises of Setterwalls Advokatbyrå at [ …
Upcoming Events
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in MayQUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to PlanHalf-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLEQUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completedCorrection: Ascelia Pharma publishes annual report for 2022